Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 14/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485290 | 1.00 | KCNH2 (1.00) | KCNH2GAAALDH1A1TSHRHSD17B10 | |
| SCHEMBL4485283 | 1.00 | KCNH2 (1.00) | KCNH2GAAALDH1A1TSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL4485249 | 0.99 | KCNH2 (0.98) | KCNH2GAA | |
| Hydrochloric Acid SCHEMBL4485248 | 0.99 | KCNH2 (0.98) | KCNH2GAA | |
| Hydrochloric Acid SCHEMBL4485251 | 0.99 | KCNH2 (0.98) | KCNH2GAA | |
| SCHEMBL4496596 | 0.90 | KCNH2 (0.82) | KCNH2 | |
| SCHEMBL4496588 | 0.90 | KCNH2 (0.82) | KCNH2 | |
| SCHEMBL4496583 | 0.90 | KCNH2 (0.82) | KCNH2 | |
| SCHEMBL13633348 | 0.90 | KCNH2 (0.81) | KCNH2 | |
| Hydrochloric Acid SCHEMBL4483213 | 0.90 | KCNH2 (0.81) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | claimed |
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1537123-B1 | AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081650-A1 | Antimicrobial Compounds | ELANE, NISCH, PIGS | KCNH2 3731/4885GAA 946/4885ALDH1A1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.